Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease.

PURPOSE: This research study is collecting bone marrow and blood samples from patients with metastatic choroid melanoma.


Clinical Trial Description

OBJECTIVES:

Primary

- Develop and validate a method of detecting tumor cells in the bone marrow and blood in patients with metastatic choroid melanoma.

OUTLINE: While patients are under general anesthesia for standard treatment of their disease, samples of bone marrow from the iliac crest and blood are collected. Samples are analyzed for the expression of tyrosinase and Melan-a via RT-PCR. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00897624
Study type Observational
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase N/A
Start date November 2007

See also
  Status Clinical Trial Phase
Recruiting NCT01217398 - Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Phase 2
Completed NCT00471471 - Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Phase 1
Completed NCT00398073 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma N/A
Completed NCT00334776 - Vaccine Therapy in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00025181 - Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery Phase 1
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00003339 - Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Completed NCT00084656 - Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Phase 2
Completed NCT00705640 - Vaccine Therapy in Treating Patients With Advanced Melanoma Phase 1
Recruiting NCT00489944 - Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Phase 2
Completed NCT00027742 - Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Phase 2
Completed NCT00952939 - Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye N/A
Terminated NCT00005841 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Phase 1
Completed NCT00089219 - Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Phase 1/Phase 2
Completed NCT00072345 - Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Phase 2
Completed NCT00243061 - AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Phase 2
Completed NCT00445965 - Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase 2
Terminated NCT00110123 - Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Phase 3
Completed NCT00032045 - Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00238329 - PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Phase 2